http://142-54-23-223.fusionmedialtd.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 14 Jul 2026 07:30:27 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://142-54-23-223.fusionmedialtd.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Management+Changes/Ironwood+names+new+CMO+as+STARS-2+trial+begins+recruiting/26764829.html <p>Ironwood Pharmaceuticals (Nasdaq: IRWD) announced the appointment of Dr. Jeffrey Silber as Chief Medical Officer and Head of Research and Drug Development, succeeding Dr. Michael Shetzline, who is retiring after a 30-year career.</p> <p>Dr. Silber joins the Boston-based biotechnology company on July 20, 2026. He will oversee Research and Drug Development, Regulatory Affairs and Medical Affairs, reporting to Chief Executive Officer Tom McCourt. Dr. Shetzline will remain as an advisor during the transition.</p> <p>Dr. Silber joins Ironwood from Vedanta Biosciences, where he served as Chief Medical Officer since 2020. Prior to that role, he held senior positions at EMD Serono/Merck KGaA, AbbVie, http://www.streetinsider.com/Management+Changes/Ironwood+names+new+CMO+as+STARS-2+trial+begins+recruiting/26764829.html Tue, 14 Jul 2026 07:30:27 -0400 A.03607790 A.07880129 A.16949560 A.20986375 A.27675538 A.50200193 IRWD O.00037398 O.00052901 O.00448140 O.20147506 O.20831026 O.21200813 O.28834655 http://www.streetinsider.com/Management+Changes/Ironwood+names+new+CMO+as+STARS-2+trial+begins+recruiting/26764829.html <p>Ironwood Pharmaceuticals (Nasdaq: IRWD) announced the appointment of Dr. Jeffrey Silber as Chief Medical Officer and Head of Research and Drug Development, succeeding Dr. Michael Shetzline, who is retiring after a 30-year career.</p> <p>Dr. Silber joins the Boston-based biotechnology company on July 20, 2026. He will oversee Research and Drug Development, Regulatory Affairs and Medical Affairs, reporting to Chief Executive Officer Tom McCourt. Dr. Shetzline will remain as an advisor during the transition.</p> <p>Dr. Silber joins Ironwood from Vedanta Biosciences, where he served as Chief Medical Officer since 2020. Prior to that role, he held senior positions at EMD Serono/Merck KGaA, AbbVie, http://www.streetinsider.com/Management+Changes/Ironwood+names+new+CMO+as+STARS-2+trial+begins+recruiting/26764829.html Tue, 14 Jul 2026 07:30:27 -0400 A.03607790 A.07880129 A.16949560 A.20986375 A.27675538 A.50200193 IRWD O.00037398 O.00052901 O.00448140 O.20147506 O.20831026 O.21200813 O.28834655 http://www.streetinsider.com/Management+Changes/Ironwood+names+new+CMO+as+STARS-2+trial+begins+recruiting/26764829.html <p>Ironwood Pharmaceuticals (Nasdaq: IRWD) announced the appointment of Dr. Jeffrey Silber as Chief Medical Officer and Head of Research and Drug Development, succeeding Dr. Michael Shetzline, who is retiring after a 30-year career.</p> <p>Dr. Silber joins the Boston-based biotechnology company on July 20, 2026. He will oversee Research and Drug Development, Regulatory Affairs and Medical Affairs, reporting to Chief Executive Officer Tom McCourt. Dr. Shetzline will remain as an advisor during the transition.</p> <p>Dr. Silber joins Ironwood from Vedanta Biosciences, where he served as Chief Medical Officer since 2020. Prior to that role, he held senior positions at EMD Serono/Merck KGaA, AbbVie, http://www.streetinsider.com/Management+Changes/Ironwood+names+new+CMO+as+STARS-2+trial+begins+recruiting/26764829.html Tue, 14 Jul 2026 07:30:27 -0400 A.03607790 A.07880129 A.16949560 A.20986375 A.27675538 A.50200193 IRWD O.00037398 O.00052901 O.00448140 O.20147506 O.20831026 O.21200813 O.28834655 http://www.streetinsider.com/Management+Changes/Ironwood+names+new+CMO+as+STARS-2+trial+begins+recruiting/26764829.html <p>Ironwood Pharmaceuticals (Nasdaq: IRWD) announced the appointment of Dr. Jeffrey Silber as Chief Medical Officer and Head of Research and Drug Development, succeeding Dr. Michael Shetzline, who is retiring after a 30-year career.</p> <p>Dr. Silber joins the Boston-based biotechnology company on July 20, 2026. He will oversee Research and Drug Development, Regulatory Affairs and Medical Affairs, reporting to Chief Executive Officer Tom McCourt. Dr. Shetzline will remain as an advisor during the transition.</p> <p>Dr. Silber joins Ironwood from Vedanta Biosciences, where he served as Chief Medical Officer since 2020. Prior to that role, he held senior positions at EMD Serono/Merck KGaA, AbbVie, http://www.streetinsider.com/Management+Changes/Ironwood+names+new+CMO+as+STARS-2+trial+begins+recruiting/26764829.html Tue, 14 Jul 2026 07:30:27 -0400 A.03607790 A.07880129 A.16949560 A.20986375 A.27675538 A.50200193 IRWD O.00037398 O.00052901 O.00448140 O.20147506 O.20831026 O.21200813 O.28834655 http://www.streetinsider.com/Management+Changes/Ironwood+names+new+CMO+as+STARS-2+trial+begins+recruiting/26764829.html <p>Ironwood Pharmaceuticals (Nasdaq: IRWD) announced the appointment of Dr. Jeffrey Silber as Chief Medical Officer and Head of Research and Drug Development, succeeding Dr. Michael Shetzline, who is retiring after a 30-year career.</p> <p>Dr. Silber joins the Boston-based biotechnology company on July 20, 2026. He will oversee Research and Drug Development, Regulatory Affairs and Medical Affairs, reporting to Chief Executive Officer Tom McCourt. Dr. Shetzline will remain as an advisor during the transition.</p> <p>Dr. Silber joins Ironwood from Vedanta Biosciences, where he served as Chief Medical Officer since 2020. Prior to that role, he held senior positions at EMD Serono/Merck KGaA, AbbVie, http://www.streetinsider.com/Management+Changes/Ironwood+names+new+CMO+as+STARS-2+trial+begins+recruiting/26764829.html Tue, 14 Jul 2026 07:30:27 -0400 A.03607790 A.07880129 A.16949560 A.20986375 A.27675538 A.50200193 IRWD O.00037398 O.00052901 O.00448140 O.20147506 O.20831026 O.21200813 O.28834655 http://www.streetinsider.com/Management+Changes/Ironwood+names+new+CMO+as+STARS-2+trial+begins+recruiting/26764829.html <p>Ironwood Pharmaceuticals (Nasdaq: IRWD) announced the appointment of Dr. Jeffrey Silber as Chief Medical Officer and Head of Research and Drug Development, succeeding Dr. Michael Shetzline, who is retiring after a 30-year career.</p> <p>Dr. Silber joins the Boston-based biotechnology company on July 20, 2026. He will oversee Research and Drug Development, Regulatory Affairs and Medical Affairs, reporting to Chief Executive Officer Tom McCourt. Dr. Shetzline will remain as an advisor during the transition.</p> <p>Dr. Silber joins Ironwood from Vedanta Biosciences, where he served as Chief Medical Officer since 2020. Prior to that role, he held senior positions at EMD Serono/Merck KGaA, AbbVie, http://www.streetinsider.com/Management+Changes/Ironwood+names+new+CMO+as+STARS-2+trial+begins+recruiting/26764829.html Tue, 14 Jul 2026 07:30:27 -0400 A.03607790 A.07880129 A.16949560 A.20986375 A.27675538 A.50200193 IRWD O.00037398 O.00052901 O.00448140 O.20147506 O.20831026 O.21200813 O.28834655 http://www.streetinsider.com/Management+Changes/Ironwood+names+new+CMO+as+STARS-2+trial+begins+recruiting/26764829.html <p>Ironwood Pharmaceuticals (Nasdaq: IRWD) announced the appointment of Dr. Jeffrey Silber as Chief Medical Officer and Head of Research and Drug Development, succeeding Dr. Michael Shetzline, who is retiring after a 30-year career.</p> <p>Dr. Silber joins the Boston-based biotechnology company on July 20, 2026. He will oversee Research and Drug Development, Regulatory Affairs and Medical Affairs, reporting to Chief Executive Officer Tom McCourt. Dr. Shetzline will remain as an advisor during the transition.</p> <p>Dr. Silber joins Ironwood from Vedanta Biosciences, where he served as Chief Medical Officer since 2020. Prior to that role, he held senior positions at EMD Serono/Merck KGaA, AbbVie, http://www.streetinsider.com/Management+Changes/Ironwood+names+new+CMO+as+STARS-2+trial+begins+recruiting/26764829.html Tue, 14 Jul 2026 07:30:27 -0400 A.03607790 A.07880129 A.16949560 A.20986375 A.27675538 A.50200193 IRWD O.00037398 O.00052901 O.00448140 O.20147506 O.20831026 O.21200813 O.28834655 http://www.streetinsider.com/Management+Changes/Ironwood+names+new+CMO+as+STARS-2+trial+begins+recruiting/26764829.html <p>Ironwood Pharmaceuticals (Nasdaq: IRWD) announced the appointment of Dr. Jeffrey Silber as Chief Medical Officer and Head of Research and Drug Development, succeeding Dr. Michael Shetzline, who is retiring after a 30-year career.</p> <p>Dr. Silber joins the Boston-based biotechnology company on July 20, 2026. He will oversee Research and Drug Development, Regulatory Affairs and Medical Affairs, reporting to Chief Executive Officer Tom McCourt. Dr. Shetzline will remain as an advisor during the transition.</p> <p>Dr. Silber joins Ironwood from Vedanta Biosciences, where he served as Chief Medical Officer since 2020. Prior to that role, he held senior positions at EMD Serono/Merck KGaA, AbbVie, http://www.streetinsider.com/Management+Changes/Ironwood+names+new+CMO+as+STARS-2+trial+begins+recruiting/26764829.html Tue, 14 Jul 2026 07:30:27 -0400 A.03607790 A.07880129 A.16949560 A.20986375 A.27675538 A.50200193 IRWD O.00037398 O.00052901 O.00448140 O.20147506 O.20831026 O.21200813 O.28834655 http://www.streetinsider.com/Management+Changes/Ironwood+names+new+CMO+as+STARS-2+trial+begins+recruiting/26764829.html <p>Ironwood Pharmaceuticals (Nasdaq: IRWD) announced the appointment of Dr. Jeffrey Silber as Chief Medical Officer and Head of Research and Drug Development, succeeding Dr. Michael Shetzline, who is retiring after a 30-year career.</p> <p>Dr. Silber joins the Boston-based biotechnology company on July 20, 2026. He will oversee Research and Drug Development, Regulatory Affairs and Medical Affairs, reporting to Chief Executive Officer Tom McCourt. Dr. Shetzline will remain as an advisor during the transition.</p> <p>Dr. Silber joins Ironwood from Vedanta Biosciences, where he served as Chief Medical Officer since 2020. Prior to that role, he held senior positions at EMD Serono/Merck KGaA, AbbVie, http://www.streetinsider.com/Management+Changes/Ironwood+names+new+CMO+as+STARS-2+trial+begins+recruiting/26764829.html Tue, 14 Jul 2026 07:30:27 -0400 A.03607790 A.07880129 A.16949560 A.20986375 A.27675538 A.50200193 IRWD O.00037398 O.00052901 O.00448140 O.20147506 O.20831026 O.21200813 O.28834655 http://www.streetinsider.com/Management+Changes/Ironwood+names+new+CMO+as+STARS-2+trial+begins+recruiting/26764829.html <p>Ironwood Pharmaceuticals (Nasdaq: IRWD) announced the appointment of Dr. Jeffrey Silber as Chief Medical Officer and Head of Research and Drug Development, succeeding Dr. Michael Shetzline, who is retiring after a 30-year career.</p> <p>Dr. Silber joins the Boston-based biotechnology company on July 20, 2026. He will oversee Research and Drug Development, Regulatory Affairs and Medical Affairs, reporting to Chief Executive Officer Tom McCourt. Dr. Shetzline will remain as an advisor during the transition.</p> <p>Dr. Silber joins Ironwood from Vedanta Biosciences, where he served as Chief Medical Officer since 2020. Prior to that role, he held senior positions at EMD Serono/Merck KGaA, AbbVie, http://www.streetinsider.com/Management+Changes/Ironwood+names+new+CMO+as+STARS-2+trial+begins+recruiting/26764829.html Tue, 14 Jul 2026 07:30:27 -0400 A.03607790 A.07880129 A.16949560 A.20986375 A.27675538 A.50200193 IRWD O.00037398 O.00052901 O.00448140 O.20147506 O.20831026 O.21200813 O.28834655 http://www.streetinsider.com/Management+Changes/Ironwood+names+new+CMO+as+STARS-2+trial+begins+recruiting/26764829.html <p>Ironwood Pharmaceuticals (Nasdaq: IRWD) announced the appointment of Dr. Jeffrey Silber as Chief Medical Officer and Head of Research and Drug Development, succeeding Dr. Michael Shetzline, who is retiring after a 30-year career.</p> <p>Dr. Silber joins the Boston-based biotechnology company on July 20, 2026. He will oversee Research and Drug Development, Regulatory Affairs and Medical Affairs, reporting to Chief Executive Officer Tom McCourt. Dr. Shetzline will remain as an advisor during the transition.</p> <p>Dr. Silber joins Ironwood from Vedanta Biosciences, where he served as Chief Medical Officer since 2020. Prior to that role, he held senior positions at EMD Serono/Merck KGaA, AbbVie, http://www.streetinsider.com/Management+Changes/Ironwood+names+new+CMO+as+STARS-2+trial+begins+recruiting/26764829.html Tue, 14 Jul 2026 07:30:27 -0400 A.03607790 A.07880129 A.16949560 A.20986375 A.27675538 A.50200193 IRWD O.00037398 O.00052901 O.00448140 O.20147506 O.20831026 O.21200813 O.28834655 http://www.streetinsider.com/Management+Changes/Ironwood+names+new+CMO+as+STARS-2+trial+begins+recruiting/26764829.html <p>Ironwood Pharmaceuticals (Nasdaq: IRWD) announced the appointment of Dr. Jeffrey Silber as Chief Medical Officer and Head of Research and Drug Development, succeeding Dr. Michael Shetzline, who is retiring after a 30-year career.</p> <p>Dr. Silber joins the Boston-based biotechnology company on July 20, 2026. He will oversee Research and Drug Development, Regulatory Affairs and Medical Affairs, reporting to Chief Executive Officer Tom McCourt. Dr. Shetzline will remain as an advisor during the transition.</p> <p>Dr. Silber joins Ironwood from Vedanta Biosciences, where he served as Chief Medical Officer since 2020. Prior to that role, he held senior positions at EMD Serono/Merck KGaA, AbbVie, http://www.streetinsider.com/Management+Changes/Ironwood+names+new+CMO+as+STARS-2+trial+begins+recruiting/26764829.html Tue, 14 Jul 2026 07:30:27 -0400 A.03607790 A.07880129 A.16949560 A.20986375 A.27675538 A.50200193 IRWD O.00037398 O.00052901 O.00448140 O.20147506 O.20831026 O.21200813 O.28834655 http://www.streetinsider.com/Management+Changes/Ironwood+names+new+CMO+as+STARS-2+trial+begins+recruiting/26764829.html <p>Ironwood Pharmaceuticals (Nasdaq: IRWD) announced the appointment of Dr. Jeffrey Silber as Chief Medical Officer and Head of Research and Drug Development, succeeding Dr. Michael Shetzline, who is retiring after a 30-year career.</p> <p>Dr. Silber joins the Boston-based biotechnology company on July 20, 2026. He will oversee Research and Drug Development, Regulatory Affairs and Medical Affairs, reporting to Chief Executive Officer Tom McCourt. Dr. Shetzline will remain as an advisor during the transition.</p> <p>Dr. Silber joins Ironwood from Vedanta Biosciences, where he served as Chief Medical Officer since 2020. Prior to that role, he held senior positions at EMD Serono/Merck KGaA, AbbVie, http://www.streetinsider.com/Management+Changes/Ironwood+names+new+CMO+as+STARS-2+trial+begins+recruiting/26764829.html Tue, 14 Jul 2026 07:30:27 -0400 A.03607790 A.07880129 A.16949560 A.20986375 A.27675538 A.50200193 IRWD O.00037398 O.00052901 O.00448140 O.20147506 O.20831026 O.21200813 O.28834655 http://www.streetinsider.com/Management+Changes/Ironwood+names+new+CMO+as+STARS-2+trial+begins+recruiting/26764829.html <p>Ironwood Pharmaceuticals (Nasdaq: IRWD) announced the appointment of Dr. Jeffrey Silber as Chief Medical Officer and Head of Research and Drug Development, succeeding Dr. Michael Shetzline, who is retiring after a 30-year career.</p> <p>Dr. Silber joins the Boston-based biotechnology company on July 20, 2026. He will oversee Research and Drug Development, Regulatory Affairs and Medical Affairs, reporting to Chief Executive Officer Tom McCourt. Dr. Shetzline will remain as an advisor during the transition.</p> <p>Dr. Silber joins Ironwood from Vedanta Biosciences, where he served as Chief Medical Officer since 2020. Prior to that role, he held senior positions at EMD Serono/Merck KGaA, AbbVie, http://www.streetinsider.com/Management+Changes/Ironwood+names+new+CMO+as+STARS-2+trial+begins+recruiting/26764829.html Tue, 14 Jul 2026 07:30:27 -0400 A.03607790 A.07880129 A.16949560 A.20986375 A.27675538 A.50200193 IRWD O.00037398 O.00052901 O.00448140 O.20147506 O.20831026 O.21200813 O.28834655 http://www.streetinsider.com/Press+Releases/Ironwood+Appoints+Dr.+Jeffrey+Silber+Chief+Medical+Officer+and+Head+of+Research+and+Drug+Development%3B+STARS-2+Trial+Initiated+in+June+and+Is+Now+Actively+Recruiting+Patients/26764821.html <p class="bwalignc"> – <i>Ironwood Chief Medical Officer and Head of Research and Drug Development </i><i>Dr. Michael Shetzline to Retire After 30-Year Career Advancing GI Science and </i><i>Patient Care</i> <i>–</i> </p><p class="bwalignc"> <i>– Dr. Silber, a Drug Development Veteran, Will Lead Ironwood’s Next Phase of R&amp;D Strategy and Execution –</i> </p> <p> BOSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fironwoodpharma.com%2F&amp;esheet=54569924&amp;newsitemid=20260714515996&amp;lan=en-US&amp;anchor=Ironwood+Pharmaceuticals%2C+Inc.&amp;index=1&amp;md5=395fabf483eb4db96a1b5692d7f6aa35" shape="rect">Ironwood Pharmaceuticals, Inc.</a> (Nasdaq: IRWD), a biotechnology company developing and commercializing life‑changing therapies for people living with gastrointestinal (GI) and rare diseases, today announced the retirement of Chief Medical Officer and Head of Research and Drug Development Dr. Michael Shetzline and the appointment of Dr. Jeffrey http://www.streetinsider.com/Press+Releases/Ironwood+Appoints+Dr.+Jeffrey+Silber+Chief+Medical+Officer+and+Head+of+Research+and+Drug+Development%3B+STARS-2+Trial+Initiated+in+June+and+Is+Now+Actively+Recruiting+Patients/26764821.html Tue, 14 Jul 2026 07:30:00 -0400 A.03607790 A.07880129 A.16949560 A.20986375 A.27675538 A.50200193 IRWD O.00037398 O.00052901 O.00448140 O.20147506 O.20831026 O.21200813 O.28834655 http://www.streetinsider.com/Press+Releases/Ironwood+Appoints+Dr.+Jeffrey+Silber+Chief+Medical+Officer+and+Head+of+Research+and+Drug+Development%3B+STARS-2+Trial+Initiated+in+June+and+Is+Now+Actively+Recruiting+Patients/26764821.html <p class="bwalignc"> – <i>Ironwood Chief Medical Officer and Head of Research and Drug Development </i><i>Dr. Michael Shetzline to Retire After 30-Year Career Advancing GI Science and </i><i>Patient Care</i> <i>–</i> </p><p class="bwalignc"> <i>– Dr. Silber, a Drug Development Veteran, Will Lead Ironwood’s Next Phase of R&amp;D Strategy and Execution –</i> </p> <p> BOSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fironwoodpharma.com%2F&amp;esheet=54569924&amp;newsitemid=20260714515996&amp;lan=en-US&amp;anchor=Ironwood+Pharmaceuticals%2C+Inc.&amp;index=1&amp;md5=395fabf483eb4db96a1b5692d7f6aa35" shape="rect">Ironwood Pharmaceuticals, Inc.</a> (Nasdaq: IRWD), a biotechnology company developing and commercializing life‑changing therapies for people living with gastrointestinal (GI) and rare diseases, today announced the retirement of Chief Medical Officer and Head of Research and Drug Development Dr. Michael Shetzline and the appointment of Dr. Jeffrey http://www.streetinsider.com/Press+Releases/Ironwood+Appoints+Dr.+Jeffrey+Silber+Chief+Medical+Officer+and+Head+of+Research+and+Drug+Development%3B+STARS-2+Trial+Initiated+in+June+and+Is+Now+Actively+Recruiting+Patients/26764821.html Tue, 14 Jul 2026 07:30:00 -0400 A.03607790 A.07880129 A.16949560 A.20986375 A.27675538 A.50200193 IRWD O.00037398 O.00052901 O.00448140 O.20147506 O.20831026 O.21200813 O.28834655 http://www.streetinsider.com/Press+Releases/Ironwood+Appoints+Dr.+Jeffrey+Silber+Chief+Medical+Officer+and+Head+of+Research+and+Drug+Development%3B+STARS-2+Trial+Initiated+in+June+and+Is+Now+Actively+Recruiting+Patients/26764821.html <p class="bwalignc"> – <i>Ironwood Chief Medical Officer and Head of Research and Drug Development </i><i>Dr. Michael Shetzline to Retire After 30-Year Career Advancing GI Science and </i><i>Patient Care</i> <i>–</i> </p><p class="bwalignc"> <i>– Dr. Silber, a Drug Development Veteran, Will Lead Ironwood’s Next Phase of R&amp;D Strategy and Execution –</i> </p> <p> BOSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fironwoodpharma.com%2F&amp;esheet=54569924&amp;newsitemid=20260714515996&amp;lan=en-US&amp;anchor=Ironwood+Pharmaceuticals%2C+Inc.&amp;index=1&amp;md5=395fabf483eb4db96a1b5692d7f6aa35" shape="rect">Ironwood Pharmaceuticals, Inc.</a> (Nasdaq: IRWD), a biotechnology company developing and commercializing life‑changing therapies for people living with gastrointestinal (GI) and rare diseases, today announced the retirement of Chief Medical Officer and Head of Research and Drug Development Dr. Michael Shetzline and the appointment of Dr. Jeffrey http://www.streetinsider.com/Press+Releases/Ironwood+Appoints+Dr.+Jeffrey+Silber+Chief+Medical+Officer+and+Head+of+Research+and+Drug+Development%3B+STARS-2+Trial+Initiated+in+June+and+Is+Now+Actively+Recruiting+Patients/26764821.html Tue, 14 Jul 2026 07:30:00 -0400 A.03607790 A.07880129 A.16949560 A.20986375 A.27675538 A.50200193 IRWD O.00037398 O.00052901 O.00448140 O.20147506 O.20831026 O.21200813 O.28834655 http://www.streetinsider.com/Press+Releases/Ironwood+Appoints+Dr.+Jeffrey+Silber+Chief+Medical+Officer+and+Head+of+Research+and+Drug+Development%3B+STARS-2+Trial+Initiated+in+June+and+Is+Now+Actively+Recruiting+Patients/26764821.html <p class="bwalignc"> – <i>Ironwood Chief Medical Officer and Head of Research and Drug Development </i><i>Dr. Michael Shetzline to Retire After 30-Year Career Advancing GI Science and </i><i>Patient Care</i> <i>–</i> </p><p class="bwalignc"> <i>– Dr. Silber, a Drug Development Veteran, Will Lead Ironwood’s Next Phase of R&amp;D Strategy and Execution –</i> </p> <p> BOSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fironwoodpharma.com%2F&amp;esheet=54569924&amp;newsitemid=20260714515996&amp;lan=en-US&amp;anchor=Ironwood+Pharmaceuticals%2C+Inc.&amp;index=1&amp;md5=395fabf483eb4db96a1b5692d7f6aa35" shape="rect">Ironwood Pharmaceuticals, Inc.</a> (Nasdaq: IRWD), a biotechnology company developing and commercializing life‑changing therapies for people living with gastrointestinal (GI) and rare diseases, today announced the retirement of Chief Medical Officer and Head of Research and Drug Development Dr. Michael Shetzline and the appointment of Dr. Jeffrey http://www.streetinsider.com/Press+Releases/Ironwood+Appoints+Dr.+Jeffrey+Silber+Chief+Medical+Officer+and+Head+of+Research+and+Drug+Development%3B+STARS-2+Trial+Initiated+in+June+and+Is+Now+Actively+Recruiting+Patients/26764821.html Tue, 14 Jul 2026 07:30:00 -0400 A.03607790 A.07880129 A.16949560 A.20986375 A.27675538 A.50200193 IRWD O.00037398 O.00052901 O.00448140 O.20147506 O.20831026 O.21200813 O.28834655 http://www.streetinsider.com/Press+Releases/Ironwood+Appoints+Dr.+Jeffrey+Silber+Chief+Medical+Officer+and+Head+of+Research+and+Drug+Development%3B+STARS-2+Trial+Initiated+in+June+and+Is+Now+Actively+Recruiting+Patients/26764821.html <p class="bwalignc"> – <i>Ironwood Chief Medical Officer and Head of Research and Drug Development </i><i>Dr. Michael Shetzline to Retire After 30-Year Career Advancing GI Science and </i><i>Patient Care</i> <i>–</i> </p><p class="bwalignc"> <i>– Dr. Silber, a Drug Development Veteran, Will Lead Ironwood’s Next Phase of R&amp;D Strategy and Execution –</i> </p> <p> BOSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fironwoodpharma.com%2F&amp;esheet=54569924&amp;newsitemid=20260714515996&amp;lan=en-US&amp;anchor=Ironwood+Pharmaceuticals%2C+Inc.&amp;index=1&amp;md5=395fabf483eb4db96a1b5692d7f6aa35" shape="rect">Ironwood Pharmaceuticals, Inc.</a> (Nasdaq: IRWD), a biotechnology company developing and commercializing life‑changing therapies for people living with gastrointestinal (GI) and rare diseases, today announced the retirement of Chief Medical Officer and Head of Research and Drug Development Dr. Michael Shetzline and the appointment of Dr. Jeffrey http://www.streetinsider.com/Press+Releases/Ironwood+Appoints+Dr.+Jeffrey+Silber+Chief+Medical+Officer+and+Head+of+Research+and+Drug+Development%3B+STARS-2+Trial+Initiated+in+June+and+Is+Now+Actively+Recruiting+Patients/26764821.html Tue, 14 Jul 2026 07:30:00 -0400 A.03607790 A.07880129 A.16949560 A.20986375 A.27675538 A.50200193 IRWD O.00037398 O.00052901 O.00448140 O.20147506 O.20831026 O.21200813 O.28834655 http://www.streetinsider.com/Press+Releases/Ironwood+Appoints+Dr.+Jeffrey+Silber+Chief+Medical+Officer+and+Head+of+Research+and+Drug+Development%3B+STARS-2+Trial+Initiated+in+June+and+Is+Now+Actively+Recruiting+Patients/26764821.html <p class="bwalignc"> – <i>Ironwood Chief Medical Officer and Head of Research and Drug Development </i><i>Dr. Michael Shetzline to Retire After 30-Year Career Advancing GI Science and </i><i>Patient Care</i> <i>–</i> </p><p class="bwalignc"> <i>– Dr. Silber, a Drug Development Veteran, Will Lead Ironwood’s Next Phase of R&amp;D Strategy and Execution –</i> </p> <p> BOSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fironwoodpharma.com%2F&amp;esheet=54569924&amp;newsitemid=20260714515996&amp;lan=en-US&amp;anchor=Ironwood+Pharmaceuticals%2C+Inc.&amp;index=1&amp;md5=395fabf483eb4db96a1b5692d7f6aa35" shape="rect">Ironwood Pharmaceuticals, Inc.</a> (Nasdaq: IRWD), a biotechnology company developing and commercializing life‑changing therapies for people living with gastrointestinal (GI) and rare diseases, today announced the retirement of Chief Medical Officer and Head of Research and Drug Development Dr. Michael Shetzline and the appointment of Dr. Jeffrey http://www.streetinsider.com/Press+Releases/Ironwood+Appoints+Dr.+Jeffrey+Silber+Chief+Medical+Officer+and+Head+of+Research+and+Drug+Development%3B+STARS-2+Trial+Initiated+in+June+and+Is+Now+Actively+Recruiting+Patients/26764821.html Tue, 14 Jul 2026 07:30:00 -0400 A.03607790 A.07880129 A.16949560 A.20986375 A.27675538 A.50200193 IRWD O.00037398 O.00052901 O.00448140 O.20147506 O.20831026 O.21200813 O.28834655 http://www.streetinsider.com/Press+Releases/Ironwood+Appoints+Dr.+Jeffrey+Silber+Chief+Medical+Officer+and+Head+of+Research+and+Drug+Development%3B+STARS-2+Trial+Initiated+in+June+and+Is+Now+Actively+Recruiting+Patients/26764821.html <p class="bwalignc"> – <i>Ironwood Chief Medical Officer and Head of Research and Drug Development </i><i>Dr. Michael Shetzline to Retire After 30-Year Career Advancing GI Science and </i><i>Patient Care</i> <i>–</i> </p><p class="bwalignc"> <i>– Dr. Silber, a Drug Development Veteran, Will Lead Ironwood’s Next Phase of R&amp;D Strategy and Execution –</i> </p> <p> BOSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fironwoodpharma.com%2F&amp;esheet=54569924&amp;newsitemid=20260714515996&amp;lan=en-US&amp;anchor=Ironwood+Pharmaceuticals%2C+Inc.&amp;index=1&amp;md5=395fabf483eb4db96a1b5692d7f6aa35" shape="rect">Ironwood Pharmaceuticals, Inc.</a> (Nasdaq: IRWD), a biotechnology company developing and commercializing life‑changing therapies for people living with gastrointestinal (GI) and rare diseases, today announced the retirement of Chief Medical Officer and Head of Research and Drug Development Dr. Michael Shetzline and the appointment of Dr. Jeffrey http://www.streetinsider.com/Press+Releases/Ironwood+Appoints+Dr.+Jeffrey+Silber+Chief+Medical+Officer+and+Head+of+Research+and+Drug+Development%3B+STARS-2+Trial+Initiated+in+June+and+Is+Now+Actively+Recruiting+Patients/26764821.html Tue, 14 Jul 2026 07:30:00 -0400 A.03607790 A.07880129 A.16949560 A.20986375 A.27675538 A.50200193 IRWD O.00037398 O.00052901 O.00448140 O.20147506 O.20831026 O.21200813 O.28834655 http://www.streetinsider.com/Press+Releases/Ironwood+Appoints+Dr.+Jeffrey+Silber+Chief+Medical+Officer+and+Head+of+Research+and+Drug+Development%3B+STARS-2+Trial+Initiated+in+June+and+Is+Now+Actively+Recruiting+Patients/26764821.html <p class="bwalignc"> – <i>Ironwood Chief Medical Officer and Head of Research and Drug Development </i><i>Dr. Michael Shetzline to Retire After 30-Year Career Advancing GI Science and </i><i>Patient Care</i> <i>–</i> </p><p class="bwalignc"> <i>– Dr. Silber, a Drug Development Veteran, Will Lead Ironwood’s Next Phase of R&amp;D Strategy and Execution –</i> </p> <p> BOSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fironwoodpharma.com%2F&amp;esheet=54569924&amp;newsitemid=20260714515996&amp;lan=en-US&amp;anchor=Ironwood+Pharmaceuticals%2C+Inc.&amp;index=1&amp;md5=395fabf483eb4db96a1b5692d7f6aa35" shape="rect">Ironwood Pharmaceuticals, Inc.</a> (Nasdaq: IRWD), a biotechnology company developing and commercializing life‑changing therapies for people living with gastrointestinal (GI) and rare diseases, today announced the retirement of Chief Medical Officer and Head of Research and Drug Development Dr. Michael Shetzline and the appointment of Dr. Jeffrey http://www.streetinsider.com/Press+Releases/Ironwood+Appoints+Dr.+Jeffrey+Silber+Chief+Medical+Officer+and+Head+of+Research+and+Drug+Development%3B+STARS-2+Trial+Initiated+in+June+and+Is+Now+Actively+Recruiting+Patients/26764821.html Tue, 14 Jul 2026 07:30:00 -0400 A.03607790 A.07880129 A.16949560 A.20986375 A.27675538 A.50200193 IRWD O.00037398 O.00052901 O.00448140 O.20147506 O.20831026 O.21200813 O.28834655 http://www.streetinsider.com/Press+Releases/Ironwood+Appoints+Dr.+Jeffrey+Silber+Chief+Medical+Officer+and+Head+of+Research+and+Drug+Development%3B+STARS-2+Trial+Initiated+in+June+and+Is+Now+Actively+Recruiting+Patients/26764821.html <p class="bwalignc"> – <i>Ironwood Chief Medical Officer and Head of Research and Drug Development </i><i>Dr. Michael Shetzline to Retire After 30-Year Career Advancing GI Science and </i><i>Patient Care</i> <i>–</i> </p><p class="bwalignc"> <i>– Dr. Silber, a Drug Development Veteran, Will Lead Ironwood’s Next Phase of R&amp;D Strategy and Execution –</i> </p> <p> BOSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fironwoodpharma.com%2F&amp;esheet=54569924&amp;newsitemid=20260714515996&amp;lan=en-US&amp;anchor=Ironwood+Pharmaceuticals%2C+Inc.&amp;index=1&amp;md5=395fabf483eb4db96a1b5692d7f6aa35" shape="rect">Ironwood Pharmaceuticals, Inc.</a> (Nasdaq: IRWD), a biotechnology company developing and commercializing life‑changing therapies for people living with gastrointestinal (GI) and rare diseases, today announced the retirement of Chief Medical Officer and Head of Research and Drug Development Dr. Michael Shetzline and the appointment of Dr. Jeffrey http://www.streetinsider.com/Press+Releases/Ironwood+Appoints+Dr.+Jeffrey+Silber+Chief+Medical+Officer+and+Head+of+Research+and+Drug+Development%3B+STARS-2+Trial+Initiated+in+June+and+Is+Now+Actively+Recruiting+Patients/26764821.html Tue, 14 Jul 2026 07:30:00 -0400 A.03607790 A.07880129 A.16949560 A.20986375 A.27675538 A.50200193 IRWD O.00037398 O.00052901 O.00448140 O.20147506 O.20831026 O.21200813 O.28834655 http://www.streetinsider.com/Press+Releases/Ironwood+Appoints+Dr.+Jeffrey+Silber+Chief+Medical+Officer+and+Head+of+Research+and+Drug+Development%3B+STARS-2+Trial+Initiated+in+June+and+Is+Now+Actively+Recruiting+Patients/26764821.html <p class="bwalignc"> – <i>Ironwood Chief Medical Officer and Head of Research and Drug Development </i><i>Dr. Michael Shetzline to Retire After 30-Year Career Advancing GI Science and </i><i>Patient Care</i> <i>–</i> </p><p class="bwalignc"> <i>– Dr. Silber, a Drug Development Veteran, Will Lead Ironwood’s Next Phase of R&amp;D Strategy and Execution –</i> </p> <p> BOSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fironwoodpharma.com%2F&amp;esheet=54569924&amp;newsitemid=20260714515996&amp;lan=en-US&amp;anchor=Ironwood+Pharmaceuticals%2C+Inc.&amp;index=1&amp;md5=395fabf483eb4db96a1b5692d7f6aa35" shape="rect">Ironwood Pharmaceuticals, Inc.</a> (Nasdaq: IRWD), a biotechnology company developing and commercializing life‑changing therapies for people living with gastrointestinal (GI) and rare diseases, today announced the retirement of Chief Medical Officer and Head of Research and Drug Development Dr. Michael Shetzline and the appointment of Dr. Jeffrey http://www.streetinsider.com/Press+Releases/Ironwood+Appoints+Dr.+Jeffrey+Silber+Chief+Medical+Officer+and+Head+of+Research+and+Drug+Development%3B+STARS-2+Trial+Initiated+in+June+and+Is+Now+Actively+Recruiting+Patients/26764821.html Tue, 14 Jul 2026 07:30:00 -0400 A.03607790 A.07880129 A.16949560 A.20986375 A.27675538 A.50200193 IRWD O.00037398 O.00052901 O.00448140 O.20147506 O.20831026 O.21200813 O.28834655 http://www.streetinsider.com/Press+Releases/Ironwood+Appoints+Dr.+Jeffrey+Silber+Chief+Medical+Officer+and+Head+of+Research+and+Drug+Development%3B+STARS-2+Trial+Initiated+in+June+and+Is+Now+Actively+Recruiting+Patients/26764821.html <p class="bwalignc"> – <i>Ironwood Chief Medical Officer and Head of Research and Drug Development </i><i>Dr. Michael Shetzline to Retire After 30-Year Career Advancing GI Science and </i><i>Patient Care</i> <i>–</i> </p><p class="bwalignc"> <i>– Dr. Silber, a Drug Development Veteran, Will Lead Ironwood’s Next Phase of R&amp;D Strategy and Execution –</i> </p> <p> BOSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fironwoodpharma.com%2F&amp;esheet=54569924&amp;newsitemid=20260714515996&amp;lan=en-US&amp;anchor=Ironwood+Pharmaceuticals%2C+Inc.&amp;index=1&amp;md5=395fabf483eb4db96a1b5692d7f6aa35" shape="rect">Ironwood Pharmaceuticals, Inc.</a> (Nasdaq: IRWD), a biotechnology company developing and commercializing life‑changing therapies for people living with gastrointestinal (GI) and rare diseases, today announced the retirement of Chief Medical Officer and Head of Research and Drug Development Dr. Michael Shetzline and the appointment of Dr. Jeffrey http://www.streetinsider.com/Press+Releases/Ironwood+Appoints+Dr.+Jeffrey+Silber+Chief+Medical+Officer+and+Head+of+Research+and+Drug+Development%3B+STARS-2+Trial+Initiated+in+June+and+Is+Now+Actively+Recruiting+Patients/26764821.html Tue, 14 Jul 2026 07:30:00 -0400 A.03607790 A.07880129 A.16949560 A.20986375 A.27675538 A.50200193 IRWD O.00037398 O.00052901 O.00448140 O.20147506 O.20831026 O.21200813 O.28834655